Simulations Plus Highlights Platform Innovation and Strategic Direction at 2026 Investor Day
MWN-AI** Summary
Simulations Plus, Inc. (Nasdaq: SLP), a leader in model-informed and AI-accelerated drug development, unveiled its strategic direction during the 2026 Virtual Investor Day. The event highlighted the Company’s mission to integrate cutting-edge AI technology with robust scientific methodologies to enhance the pharmaceutical industry's drug development processes. CEO Shawn O’Connor emphasized that the pharmaceutical sector is currently facing complex challenges, including heightened regulatory expectations and the need for faster decision-making without sacrificing scientific rigor.
The presentation underscored how Simulations Plus is poised to lead change by evolving from a series of standalone tools to a comprehensive ecosystem, integrating discovery, development, clinical operations, and commercialization processes. Co-Chief Product & Technology Officers Jonathan Chauvin and Erik Guffrey detailed the vision for a unified modeling platform that emphasizes transparency, scientific accountability, and adherence to emerging regulatory guidance from bodies like the FDA and EMA regarding AI practices in drug development.
Key discussions revolved around the industry's increasing reliance on in silico evidence, model-informed drug development (MIDD), and non-animal methodologies, signaling a significant shift toward more integrated and scalable solutions. The company is also prioritizing the development of scalable, cloud-based systems and AI-assisted workflows aimed at improving productivity while ensuring documentation is regulator-ready and reproducible.
As Simulations Plus continues to strive for long-term value creation, the firm remains committed to its foundational principles of providing "grounded intelligence" through technology that augments rather than replaces existing scientific practices. The insights shared during the Investor Day reflect a determined effort to adapt to the drug development landscape's evolving dynamics. The replay of the presentation is available on the Simulations Plus website for further details.
MWN-AI** Analysis
At Simulations Plus’ 2026 Investor Day, key developments in platform innovation and strategic direction showcased the company's commitment to leading drug development through integrated, AI-enabled solutions. As a financial analyst, it is essential to analyze these developments in the context of market trends and strategic priorities to provide actionable advice.
Simulations Plus is positioning itself at the forefront of a crucial industry shift, where regulatory expectations and scientific complexities are rising. By leveraging AI and cloud technologies, the company aims to streamline drug development and enhance compliance with evolving standards—potentially reducing time-to-market for new therapeutics. The focus on model-informed drug development (MIDD) aligns with regulatory momentum from entities like the FDA and EMA, indicating that the demand for such solutions is likely to grow.
Investors should monitor Simulations Plus’ ability to execute its vision of creating a unified modeling ecosystem. This will not only dictate its competitive advantage but also influence revenue growth. The strategic integration of validated science with AI capabilities can enhance productivity and enable faster decision-making, which could appeal to clients under increasing pressure to deliver results.
Moreover, the emphasis on transparency and scientific accountability resonates with today’s market expectations for responsible AI usage. As drug development becomes more reliant on in silico methods, Simulations Plus stands positioned to capitalize on this demand.
In conclusion, Simulations Plus appears well-prepared to navigate the complexities of the biopharmaceutical landscape, making it an appealing candidate for investment. Stakeholders should keep a close eye on regulatory developments, competitive responses, and the company's progress toward building its integrated platform, as these factors will significantly impact its long-term value creation strategy. Investing in Simulations Plus could represent a strategic move, particularly as the demand for innovative drug development solutions continues to expand in the coming years.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Showcases platform momentum, strategic priorities, and long-term value creation outlook
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today hosted its 2026 Virtual Investor Day, outlining how the Company is advancing an integrated, AI-enabled platform to support the evolving needs of the drug development industry and its regulators.
The Investor Day presentation focused on how Simulations Plus is driving innovation and leading meaningful change across the drug development lifecycle—pairing its long-standing scientific reputation with modern cloud and AI capabilities, while maintaining clear strategic direction.
“Our industry is at an inflection point,” said Shawn O’Connor, Chief Executive Officer of Simulations Plus. “Scientific complexity is increasing, regulatory expectations are evolving, and our clients are under pressure to move faster without compromising rigor. Our strategy is intended to address these challenges by combining trusted science with modern, integrated technology—so teams can make better decisions with confidence.”
Executive leadership discussed industry dynamics shaping pharmaceutical R&D, including increasing scientific complexity, rising expectations for in silico evidence, and regulatory momentum around model-informed drug development (MIDD), non-animal methodologies (NAMs), and responsible use of AI. The Company highlighted its alignment with emerging regulatory guidance, including the U.S. Food and Drug Administration (FDA) and European Medicines Agency’s (EMA) shared principles for good AI practice in medicine development, emphasizing transparency, traceability, and scientific accountability.
“Drug development is entering a new phase—one where scale, integration, and scientific trust matter more than isolated tools,” said Jonathan Chauvin, Co-Chief Product & Technology Officer of Simulations Plus. “Our focus is on evolving our software and services into a unified modeling ecosystem that connects validated science, AI-assisted workflows, and enterprise-ready infrastructure in a way our clients and regulators can rely on.”
“At the core of our approach is grounded intelligence,” said Erik Guffrey, Co-Chief Product & Technology Officer of Simulations Plus. “We are following the FDA and EMA guiding principles of good AI practice in drug development—using AI to augment, not replace, mechanistic modeling, and ensuring outputs remain explainable, auditable, and anchored in validated science.”
The central theme of the event was Simulations Plus’ evolution from a portfolio of best-in-class tools into an orchestrated ecosystem spanning discovery, development, clinical operations, and commercialization. The Company outlined how cloud-enabled execution, reusable workflow patterns, and AI-assisted capabilities are being developed to hopefully improve productivity while supporting regulator-ready documentation and reproducibility.
The Investor Day broadcast is available for replay on the Simulations Plus website .
About Simulations Plus, Inc.
Simulations Plus is a global leader in model-informed and AI-accelerated drug development. We create value for our clients by accelerating the discovery, development, and commercialization of pharmaceuticals and other products through innovative science-based software and consulting solutions. For more information, visit www.simulations-plus.com .
Forward-Looking Statements
Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like “believe,” “will”, “can”, “expect,” “anticipate,” and similar expressions (or the negative of such terms, as well as other words or expressions referencing future events, conditions, or circumstances) mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Forward-looking statements include but are not limited to statements regarding our fiscal year 2026 guidance, revenue growth, anticipated margins and profitability, demand to software and services, the impact of pricing actions, client spending levels, market conditions, the development, capabilities, regulatory acceptance, regulatory compliance and commercialization of AI-enabled and cloud-based solutions, the timing and content of product initiatives discussed at Investor Day, and our ability to execute our long-term strategic vision. These forward-looking statements are based on current assumptions and expectations that involve risks and uncertainties that could cause the actual results to differ materially from those expressed or implied. Factors that could cause or contribute to such differences include, but are not limited to: effectiveness of our internal operational structure, our ability to maintain our competitive advantages and commercialize AI and cloud-enabled solutions, evolving regulatory and data privacy standards governing AI technologies, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, market conditions, macroeconomic factors, and a sustainable market. Further information on our risk factors is contained in our quarterly, annual, and current reports and filed with the U.S. Securities and Exchange Commission. No regulatory authority has endorsed, approved, or validated the Company’s products, platforms, or AI-related approaches.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260121307543/en/
Investor Relations Contact :
Lisa Fortuna
Financial Profiles
310-622-8251
slp@finprofiles.com
FAQ**
How does Simulations Plus Inc. SLP plan to leverage its AI-enabled platform to enhance regulatory compliance in the evolving landscape of drug development, as outlined in the recent Investor Day presentation?
What specific strategies is Simulations Plus Inc. SLP implementing to address the increasing scientific complexity and regulatory expectations in pharmaceutical R&D?
Can you elaborate on the anticipated impact of Simulations Plus Inc. SLP's unified modeling ecosystem on productivity and decision-making for clients in the drug development lifecycle?
How does Simulations Plus Inc. SLP intend to maintain its competitive advantages while commercializing AI and cloud-enabled solutions amidst the dynamic challenges in the pharmaceutical industry?
**MWN-AI FAQ is based on asking OpenAI questions about Simulations Plus Inc. (NASDAQ: SLP).
NASDAQ: SLP
SLP Trading
-3.32% G/L:
$11.94 Last:
49,748 Volume:
$12.24 Open:
